Here's Why You Should Retain Ecolab Stock in Your Portfolio Now

Ecolab Inc. ECL has been gaining from its solid product portfolio. The optimism, led by a solid first-quarter 2026 performance and continued focus on research and development, is expected to contribute further. However, concerns regarding cost fluctuations persist.This Zacks Rank #3 (Hold) stock has gained 2.3% in the year-to-date period compared with the industry’s 13% growth. The S&P 500 Composite has increased 8.9% during the same time frame.The renowned water, hygiene and infection prevention solutions and services provider has a market capitalization of $75.8 billion. It projects 14.3% growth for the next five years and expects to maintain a strong performance in the future. Ecolab’s earnings surpassed the Zacks Consensus Estimate in two of the trailing four quarters, missed once and met once, delivering an average surprise of 0.23%.Image Source: Zacks Investment ResearchReasons Favoring Ecolab’s GrowthEcolab’s Global High-Tech Business & Digital Platform: Per management, Ecolab’s Global High-Tech business remains a key long-term growth driver, supported by rising semiconductor manufacturing and data-center infrastructure investments worldwide. In first-quarter 2026, the segment delivered more than 20% organic sales growth, driven by new business wins across microelectronics and data centers. Management also noted that the Ovivo Electronics acquisition strengthens Ecolab’s ultrapure water capabilities for semiconductor fabs and, together with the pending CoolIT Systems acquisition, is expected to create a roughly $1.5 billion Global High-Tech platform.Meanwhile, Ecolab Digital continues to scale as another important growth engine, with annualized revenues surpassing $400 million. Management highlighted that the platform leverages AI, predictive analytics, remote monitoring and automation to enhance customer productivity and sustainability outcomes, while addressing a $13 billion market opportunity, including nearly $3 billion within the existing customer base.Strong Product Portfolio With a Focus on R&D: In first-quarter 2026, Ecolab’s organic sales rose 4%, driven by 3% pricing and 1% volume growth, reflecting the strong value proposition of its portfolio. Per management, the company continues to benefit from a robust innovation pipeline, with increasing focus on digitally enabled solutions that enhance customer productivity and sustainability.Platforms like 3D TRASAR and other connected monitoring solutions are gaining traction by helping customers optimize water usage, energy consumption and operational efficiency. Management noted that these technology-driven offerings deliver measurable savings, strengthen long-term customer relationships and support premium pricing, reinforcing Ecolab’s competitive position across its end markets.Strong Q1 Results: ECL exited the first quarter of 2026 with in-line earnings and better-than-expected revenues. The company registered a robust year-over-year uptick in its top and bottom lines, along with solid performances across all segments. The expansion of the adjusted operating margin bodes well for the stock.Per management, Ecolab’s performance in the first quarter was driven by strong value pricing, accelerated volume growth and improved productivity, demonstrating the strength of its technology- and service-led model. Its core businesses also delivered strong performance as Institutional and Specialty both improved, and Food & Beverage continued to significantly outperform market trends. These looked promising for the stock.A Factor That May Offset ECL’s GainsCost Fluctuations: Ecolab faces risks from raw material cost volatility, inflationary pressures and supply-chain disruptions, which could weigh on margins and profitability. Management expects commodity costs to rise at a high single-digit rate beginning in second-quarter 2026, primarily driven by energy-related expenses.The company remains exposed to fluctuations in raw material availability and pricing, as well as challenges in renewing supply agreements on favorable terms, which could adversely impact operating results, financial position and cash flows. Additionally, geopolitical tensions and broader economic slowdowns may disrupt global sourcing and supplier performance, limiting Ecolab’s ability to secure raw materials efficiently and at competitive prices.Estimate TrendEcolab is witnessing a stable estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for its earnings has remained stable at $8.47 per share.The Zacks Consensus Estimate for the company’s second-quarter 2026 revenues is pegged at $4.4 billion, indicating a 9.4% improvement from the year-ago quarter’s reported number.Key PicksSome better-ranked stocks from the broader medical space are Globus Medical GMED, West Pharmaceutical WST and Intuitive Surgical ISRG.Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12 per share, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.West Pharmaceutical, currently flaunting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.ISRG has a long-term estimated growth rate of 14.6% compared with the industry’s 12.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.7% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>This article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks